KindlyMD (NASDAQ:NAKA) CEO David Bailey Buys 4,852 Shares of Stock

KindlyMD, Inc. (NASDAQ:NAKA) CEO David Bailey bought 4,852 shares of the stock in a transaction on Thursday, August 20th. The stock was acquired at an average price of $6.27 per share, with a total value of $30,422.04. Following the completion of the acquisition, the chief executive officer owned 3,185,246 shares of the company’s stock, valued at $19,971,492.42. This represents a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

KindlyMD Stock Up 12.1%

NASDAQ:NAKA opened at $7.06 on Friday. The firm has a market capitalization of $126.34 million, a P/E ratio of -0.20 and a beta of 15.95. KindlyMD, Inc. has a twelve month low of $3.33 and a twelve month high of $422.40. The company has a fifty day moving average of $4.54 and a 200-day moving average of $7.24.

KindlyMD (NASDAQ:NAKA) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.65) earnings per share for the quarter. KindlyMD had a negative net margin of 1,067.93% and a negative return on equity of 63.45%. The company had revenue of $35.87 million for the quarter. On average, analysts anticipate that KindlyMD, Inc. will post -11.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

NAKA has been the topic of several analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KindlyMD in a research report on Friday, August 7th. TD Cowen lifted their target price on shares of KindlyMD from $1.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, July 27th. Finally, Wall Street Zen raised KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $22.33.

KindlyMD News Summary

Here are the key news stories impacting KindlyMD this week:

• Positive Sentiment: CEO David F. Bailey purchased 4,918 shares at an average price of $5.12, investing approximately $25,180. The transaction raised his direct ownership to 3.18 million shares, which may reassure investors about management’s confidence in KindlyMD’s long-term outlook. CEO stock purchase article
• Neutral Sentiment: Maxim Group improved its EPS forecasts for the fourth quarter of 2026 and the first two quarters of 2027, projecting smaller losses of $0.48, $0.76 and $0.74 per share, respectively. These revisions are modestly encouraging but still indicate that KindlyMD is not expected to reach profitability in the near term. KindlyMD analyst estimates
• Negative Sentiment: Maxim lowered its third-quarter 2026 EPS forecast to a $0.49 loss from a $0.43 loss, cut its fourth-quarter 2027 estimate to a $0.43 loss from a $0.41 loss, and reduced its full-year 2027 forecast to a $2.12 loss from a $1.44 loss. The full-year downgrade points to weaker expected profitability and offsets some of the improved quarterly estimates.
• Negative Sentiment: KindlyMD’s latest reported quarter showed a $6.65-per-share loss on $35.87 million of revenue, alongside a deeply negative net margin. The company is expected to post a loss of approximately $11.31 per share for the current year, while analyst coverage remains mixed, including sell ratings. KindlyMD financial and insider trading data

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NAKA. Alyeska Investment Group L.P. purchased a new position in KindlyMD in the 4th quarter valued at approximately $8,993,000. ParaFi Capital LP purchased a new position in shares of KindlyMD in the third quarter valued at $443,055,000. Hunting Hill Global Capital LLC purchased a new position in shares of KindlyMD in the fourth quarter valued at $4,672,000. Yorkville Advisors Global LP bought a new stake in shares of KindlyMD during the 4th quarter valued at $3,265,000. Finally, UBS Group AG purchased a new stake in KindlyMD during the 4th quarter worth about $2,958,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.